细菌性脓毒症与COVID-19的临床表型:预后与免疫治疗指导
该研究为对前瞻性临床研究的回顾性分析,纳入希腊ICU和内科病房1498例患者(细菌性脓毒症620例,重症COVID-19 878例),采用六参数算法(肌酐、乳酸、天冬氨酸转氨酶、胆红素、C反应蛋白、国际标准化比值)将细菌性脓毒症患者分为既往定义的四种表型,并将两项开放标签免疫治疗试验中的重症COVID-19患者进行分类,评估阿那白滞素治疗效应的异质性,主要终点为28天死亡率。结果显示,该算法在细菌性脓毒症队列及其中各研究中验证了四种表型的存在;表型α为年轻、死亡风险低的患者,β与高合并症负担相关,δ死亡率最高;表型分配与结局独立相关,即使校正Charlson合并症指数后仍如此;重症COVID-19的表型分布和结局呈现相似模式。结论认为,简化算法成功识别了既往推导的细菌性脓毒症表型,这些表型可预测结局,该分类可能适用于重症COVID-19患者并具有预后意义。
要点
- 六参数算法(肌酐、乳酸、天冬氨酸转氨酶、胆红素、C反应蛋白、国际标准化比值)可在细菌性脓毒症中识别四种表型。
- 表型α为年轻、死亡风险低的患者,β与高合并症负担相关,δ死亡率最高。
- 表型分配与结局独立相关,即使校正Charlson合并症指数后仍如此。
- 重症COVID-19的表型分布和结局与细菌性脓毒症呈现相似模式。
- 研究评估了阿那白滞素治疗效应的异质性,主要终点为28天死亡率。
适用人群与场景
- 希腊ICU和内科病房收治的1498例患者,其中细菌性脓毒症620例,重症COVID-19 878例。
诊断标准与关键阈值
- 采用六参数算法(肌酐、乳酸、天冬氨酸转氨酶、胆红素、C反应蛋白、国际标准化比值)将细菌性脓毒症患者分为既往定义的四种表型。
- 该算法基于29项入院参数的既往算法简化而来。
研究设计与关键结果
- 研究类型为对前瞻性临床研究的回顾性分析,纳入1498例患者(细菌性脓毒症620例,重症COVID-19 878例),来自希腊ICU和内科病房。
- 主要终点为28天死亡率。
- 六参数算法在细菌性脓毒症队列及其中各研究中验证了四种表型的存在。
- 表型α为年轻、死亡风险低的患者,β与高合并症负担相关,δ死亡率最高。
- 表型分配与结局独立相关,即使校正Charlson合并症指数后仍如此。
- 重症COVID-19的表型分布和结局呈现相似模式。
- 评估了阿那白滞素治疗效应的异质性。
证据类型、等级与局限
- 证据类型:对前瞻性临床研究的回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,该简化算法成功识别了既往推导的细菌性脓毒症表型,这些表型可预测结局。
- 作者认为,该分类可能适用于重症COVID-19患者,具有预后意义。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: It is suggested that sepsis may be classified into four clinical phenotypes, using an algorithm employing 29 admission parameters. We applied a simplified phenotyping algorithm among patients with bacterial sepsis and severe COVID-19 and assessed characteristics and outcomes of the derived phenotypes.
DESIGN: Retrospective analysis of data from prospective clinical studies.
SETTING: Greek ICUs and Internal Medicine departments.
PATIENTS AND INTERVENTIONS: We analyzed 1498 patients, 620 with bacterial sepsis and 878 with severe COVID-19. We implemented a six-parameter algorithm (creatinine, lactate, aspartate transaminase, bilirubin, C-reactive protein, and international normalized ratio) to classify patients with bacterial sepsis intro previously defined phenotypes. Patients with severe COVID-19, included in two open-label immunotherapy trials were subsequently classified. Heterogeneity of treatment effect of anakinra was assessed. The primary outcome was 28-day mortality.
MEASUREMENTS AND MAIN RESULTS: The algorithm validated the presence of the four phenotypes across the cohort of bacterial sepsis and the individual studies included in this cohort. Phenotype α represented younger patients with low risk of death, β was associated with high comorbidity burden, and δ with the highest mortality. Phenotype assignment was independently associated with outcome, even after adjustment for Charlson Comorbidity Index. Phenotype distribution and outcomes in severe COVID-19 followed a similar pattern.
CONCLUSIONS: A simplified algorithm successfully identified previously derived phenotypes of bacterial sepsis, which were predictive of outcome. This classification may apply to patients with severe COVID-19 with prognostic implications.
参考来源
- Karakike E, Metallidis S, Poulakou G, et al. Clinical Phenotyping for Prognosis and Immunotherapy Guidance in Bacterial Sepsis and COVID-19. Crit Care Explor. 2024. PMID: 39263383. doi:10.1097/CCE.0000000000001153
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。